Research
Neural
GIPR agonism may reduce gastrointestinal adverse effects associated with GLP-1R agonism.
GIPR agonists may help mitigate gastrointestinal side effects for patients using GLP-1R agonists.
StrongSupportsmedium confidence
In animal experiments, GIPR agonism reduced GI adverse effects (AEs) induced by chemotherapeutic agents or GLP-1R agonism.
Why this rating
Based on the randomized, placebo-controlled study design.
Source
A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
Filip K. Knop et al. · Diabetes Obesity and Metabolism · 2024
rct · n=34Cited 35×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →